

0001104659-24-1011486-K ARGENX SE 2024091920240919060623060624060624 0 0001104659-24-101148 6-K 2  
20240919 20240919 20240919 ARGENX SE 0001697862 2836 0000000000 P7 1231 6-K 34 001-38097 241308764  
INDUSTRIEPARK ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE C9 B-9052 32 (9) 310 34 00 INDUSTRIEPARK  
ZWIJNAARDE 7 BUILDING C B-9052 ZWIJNAARDE C9 B-9052 argenx N.V 20170210 6-K 1 tm2424273d1 6k.htm  
FORM 6-K Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â Â  
FORMÂ 6-K Â Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934 Â For the Month of SeptemberÂ 2024 Â Commission File Number: 001-38097  
Â Â ARGENX SE (Translation of registrantâ€™s name into English) Â Â Laarderhoogtweg 25 1101 EB Amsterdam,  
the Netherlands (Address of principal executive offices) Â Â Indicate by check mark whether the registrant files or will  
file annual reports under cover of FormÂ 20-F or FormÂ 40-F. Â Form 20-F Â x Â Â Â Â Â Â Â Â Â Â Â Â  
FormÂ 40-F Â Â Â Indicate by check mark if the registrant is submitting the FormÂ 6-K in paper as permitted by  
Regulation S-T RuleÂ 101(b)(1):Â Â Â Indicate by check mark if the registrant is submitting the FormÂ 6-K in paper as  
permitted by Regulation S-T RuleÂ 101(b)(7):Â Â Â Â Â Â Â EXPLANATORY NOTE Â On SeptemberÂ 19, 2024,  
argenx SE (the â€œCompanyâ€) issued a press release, a copy of which is attached hereto as ExhibitÂ 99.1 and is  
incorporated by reference herein. Â The information contained in this Current Report on FormÂ 6-K, including  
ExhibitÂ 99.1, shall be deemed to be incorporated by reference into the Companyâ€™s Registration Statements on  
Forms F-3 (File No.Â 333-258251) and S-8 (File Nos.Â 333-225375,Â 333-258253, and 333-274721), and to be part  
thereof from the date on which this Current Report on FormÂ 6-K is filed, to the extent not superseded by documents or  
reports subsequently filed or furnished. Â Exhibit Â Description Â Â Â 99.1 Â Press Release SeptemberÂ 19, 2024 Â  
Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly  
signed this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â ARGENX SE Â Â  
Date: SeptemberÂ 19, 2024 By: Â /s/ Hemamalini (Malini) Moorthy Â Â Name: Hemamalini (Malini) Moorthy Â Â  
Title: General Counsel Â Â EX-99.1 2 tm2424273d1\_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Â argenx Announces  
Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating  
Polyneuropathy Â ADHERE was largest and most innovative clinical trial of CIDP patients to date Â VYVGARTÂ®  
Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of  
relapse and rapid onset of action Â VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-  
approved to treat CIDP Â SeptemberÂ 19, 2024 â€” 7:00 am CET Â Amsterdam, the Netherlands â€” argenx SE  
(EuronextÂ & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from  
severe autoimmune diseases, today announced publication in The Lancet Neurology of the pivotal ADHERE Study, the  
largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare, debilitating,  
often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system. This is the first time the  
ADHERE Study has been published in a peer-reviewed medical journal. A link to the full manuscript can be found here.  
Â Â Â Since its approval in June, VYVGART Hytrulo is already transforming the lives of patients with CIDP,â€ said Luc  
Truyen, M.D., Ph.D., Chief Medical Officer of argenx. â€With todayâ€™s publication in The Lancet Neurology, we are  
also advancing scientific knowledge of the disease biology underlying CIDP and thereby helping to progress further  
innovation with the potential, like VYVGART Hytrulo, to significantly improve function for patients while easing the  
burdens associated with prior treatments.â€ Â Highlights from the ADHERE study: Â Â ADHERE met its primary  
endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo  
Â 69% (221/322) of patients treated with VYVGART Hytrulo, regardless of prior treatment, demonstrated evidence of  
clinical improvement, including improvements in mobility, function and strength Â 99% of trial participants elected to  
participate in the ADHERE open-label extension Â VYVGART Hytrulo was well-tolerated and safety results were  
consistent with the known safety profile of VYVGART in previous clinical studies and real-world use Â Â Â The  
ADHERE data demonstrate that VYVGART Hytrulo has a rapid onset of action, and can reduce CIDP disease  
progression and risk of relapse: Â Â Reduced risk of relapse: VYVGART Hytrulo reduced the risk of relapse by 61% as  
assessed by aINCAT deterioration (Stage B primary endpoint) versus placebo (HR 0.394 [95% CI 0.253â€”0.614];  
p<0.0001). Â Reduced disease progression: VYVGART Hytrulo reduced the risk of CIDP disease progression based on  
time-to-first â€¥4-point decrease in I-RODS score compared with Stage B baseline (HR 0.537 [95% CI 0.354â€”0.814];  
nominal p=0.0034). Â Rapid onset of action: In Stage A, time to first improvement on aINCAT,Â I-RODS, or grip  
strength scores among the 25th percentile of patients was 9.0 days (95% CI 8.0-9.0) after the first dose of VYVGART  
Hytrulo; the median estimate was 22.0 days (15.0-23.0). Â In JuneÂ 2024, the U.S. Food and Drug Administration  
approved VYVGART Hytrulo for the treatment of adult patients with CIDP. VYVGART Hytrulo is also approved for the  
treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR)  
antibody positive. Â See FDA-approved Important Safety Information below and full Prescribing Information for  
VYVGART Hytrulo for additional information. Â What is VYVGARTÂ® HYTRULO (efgartigimod alfa and hyaluronidase-  
qvfc)? Â VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic  
inflammatory demyelinating polyneuropathy (CIDP). Â IMPORTANT SAFETY INFORMATION Â Do not use VYVGART  
HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART  
HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to  
fainting. Â VYVGART HYTRULO may cause serious side effects, including: Â Infection. VYVGART HYTRULO may  
increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract  
and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful  
urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess  
phlegm, nasal discharge, back pain, and/or chest pain. Â Allergic Reactions (hypersensitivity reactions). VYVGART  
HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were  
also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and  
decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab. Â Â Â Infusion-  
Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs  
reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.  
Â Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These  
can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause  
or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction. Â  
Before taking VYVGART HYTRULO, tell your doctor if you: Â Â take any medicines, including prescription and non-  
prescription medicines, supplements, or herbal medicines, Â have received or are scheduled to receive a vaccine

(immunization), or • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding. • What are the common side effects of VYVGART HYTRULO? • The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives. • These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088. • Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor. • About ADHERE Trial Design • The ADHERE trial was a multicenter, randomized, double-blind, placebo-controlled trial evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). ADHERE enrolled 322 adult patients with CIDP who were treatment naïve (not on active treatment within the past six months or newly diagnosed) or being treated with immunoglobulin therapy or corticosteroids. The trial consisted of an open-label Stage A followed by a randomized, placebo-controlled Stage B. In order to be eligible for the trial, the diagnosis of CIDP was confirmed by an independent panel of experts. Patients entered a run-in stage, where any ongoing CIDP treatment was stopped and in order to be eligible for Stage A had to demonstrate active disease, with clinically meaningful worsening on at least one CIDP clinical assessment tool, including INCAT, I-RODS, or mean grip strength. Treatment naïve patients were able to skip the run-in period with proof of recent worsening. To advance to Stage B, patients needed to demonstrate evidence of clinical improvement (ECI) with VYVGART Hytrulo. ECI was achieved through improvement of the INCAT score, or improvement on I-RODS or mean grip strength if those scales had demonstrated worsening during the run-in period. In Stage B, patients were randomized to either VYVGART Hytrulo or placebo for up to 48 weeks. The primary endpoint was measured once 88 total relapses or events were achieved in Stage B and was based on the hazard ratio for the time to first adjusted INCAT deterioration (i.e. relapse). After Stage B, all patients had the option to roll-over to an open-label extension study to receive VYVGART Hytrulo. • • • • About VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) • VYVGART Hytrulo is a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. In binding to the neonatal Fc receptor (FcRn), VYVGART Hytrulo results in the reduction of circulating IgG. It is the first-and-only approved FcRn blocker administered by subcutaneous injection. • About Chronic Inflammatory Demyelinating Polyneuropathy • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system. Although confirmation of disease pathophysiology is still emerging, there is increasing evidence that IgG antibodies play a key role in the damage to the peripheral nerves. People with CIDP experience fatigue, muscle weakness and a loss of feeling in their arms and legs that can get worse over time or may come and go. These symptoms can significantly impair a person's ability to function in their daily lives. Without treatment, one-third of people living with CIDP will need a wheelchair. There are approximately 24,000 patients in the U.S. currently receiving treatment for CIDP. • About argenx • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit [www.argenx.com](http://www.argenx.com) and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube. • Contacts • Media: • Ben Petok [bpetok@argenx.com](mailto:bpetok@argenx.com) • Investors: • Alexandra Roy (US) [aroy@argenx.com](mailto:aroy@argenx.com) • Lynn Elton (EU) [lelton@argenx.com](mailto:lelton@argenx.com) •